ArticleIn vivo (Athens, Greece)
Prognostic and Predictive Factors for Patients With Gastric Cancer who Are Positive for Peritoneal Lavage Cytology and Negative for Other Distant Metastasis.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThis study aimed to clarify the prognostic and predictive factors of patients with gastric cancer (GC) who are peritoneal lavage cytology positive and negative for other distant metastasis. PATIENTS AND
methodsConsecutive patients were selected from the database of Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Department of Gastric Surgery, Tokyo, Japan, according to the following criteria: i) histologically-proven gastric adenocarcinoma; ii) patients who underwent macroscopically curative gastrectomy for gastric cancer as a primary treatment; and iii) a diagnosis of peritoneal washing cytology positive (CY1) disease with no distant metastasis between 2005 and 2025.
resultsA total of 89 patients were eligible for the present study. One-, three- and five-years overall survival (OS) rates of the whole cohort were 68.6%, 41.2%, and 21.3%. Medina survival time was 22.2 months (range=11.3-33.1 months). In the prognostic analysis for OS in the CY positive patients with GC who were negative for other distant metastasis, postoperative chemotherapy status was one of the independent prognostic factors [hazard ratio (HR)=2.228, 95% confidence interval (CI)=1.330-3.734]. One-, three- and five-years OS rates of the patients with postoperative adjuvant chemotherapy were 81.1%, 46.3%, and 33.9%, while that of patients without postoperative chemotherapy were 47.6%, 32.9%, and 4.7% (
conclusionPostoperative chemotherapy improved the survival of CY positive patients with GC who were negative for other distant metastasis. In addition, lymph node metastasis status was an independent prognostic factor for CY positive patients with GC who were negative for other distant metastasis and received postoperative chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.